

## **ORD Summary: State of the Science Symposium**

In 2001, the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) chartered the Blood and Marrow Transplantation Clinical Trials Network (BMT CTN) to conduct HCT clinical trials that would advance the standard of care for transplant patients. The BMT CTN has now been operational for nearly six years with a total accrual of almost 2,000 patients. In order to frame the scientific agenda for the next five years, the network planned a State of the Science Symposium (SOSS). Intensive committee work began in September 2006, and after multiple meetings, draft reports from all twelve committees were reviewed by a panel of international experts prior to the symposium, who led the question periods in Ann Arbor. Following the presentation and discussion of the committees, the Chairs, together with several of the international panel of experts, reviewed the discussions and made recommendations. High priority was given only to those protocols with sufficient preliminary data to begin protocol design and studies that awaited completion of ongoing trials were given lower priority. General consensus of very high enthusiasm was achieved regarding the following seven protocols:

**GVHD:** Phase II trial in patients with high risk chronic GVHD (already under development).

**Multiple Myeloma:** Phase III trial in patients receiving one auto-transplant of VRD consolidation in second transplant (already under development).

**Leukemia:** Phase III trial in patients with high risk AML in CR1 of chemotherapy vs unrelated donor.

**Leukemia:** Phase III trial in patients with Ph+ALL of chemotherapy + dasatinib vs allogeneic HCT

**Leukemia:** Phase II trial of allogeneic HCT in patients with very high risk CLL.

**Quality of Life:** Phase III trial of peritransplant stress management interventions.

**Cell Therapy:** Phase II trial of HLA-matched viral specific CTLs to treat adenoviral infections.

There was also high enthusiasm for the following 4 trials:

**Pediatrics:** Phase II trial of reduced intensity allogeneic HCT for hemophagocytic lymphohistiocytosis (HLH).

**Leukemia:** Phase III trial in allogeneic HCT recipients aged 30-60 with AML of full intensity vs. reduced intensity conditioning.

**Lymphoma:** Phase II trial of reduced intensity allogeneic HCT as primary therapy for T-Cell lymphoma.

**Non Malignant Diseases:** Phase II trial of autotransplant for refractory Crohn's disease.

The symposium thus fully met the expectations to frame the BMT CTN scientific agenda for the next several years. Of note, high priority was given to a proposed trial of allogeneic HCT for the rare disease hemophagocytic lymphohistiocytosis (HLH). A summary of the symposium will be published in the journal *Biology of Blood and Marrow Transplantation*. Publication date will be late 2007 or early 2008.

Notice: Funding for this conference was also made possible in part by 1 R13 HL88882-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Departments of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.